Dynamic contrast-enhanced computed tomography imaging biomarkers correlated with immunohistochemistry for monitoring the effects of sorafenib on experimental prostate carcinomas.

Dynamic contrast-enhanced computed tomography imaging biomarkers correlated with immunohistochemistry for monitoring the effects of sorafenib on experimental prostate carcinomas.

Item
http://www.wikidata.org/entity/Q39470823
Prostate cancer detection and diagnosis: the role of MR and its comparison with other diagnostic modalities--a radiologist's perspective.Visualization, imaging and new preclinical diagnostics in radiation oncology.Assessment of prostate cancer with integrated CT-perfusion using a sector-wise approach.CT perfusion of the liver: principles and applications in oncology.Regorafenib effects on human colon carcinoma xenografts monitored by dynamic contrast-enhanced computed tomography with immunohistochemical validationMonitoring Cell Death in Regorafenib-Treated Experimental Colon Carcinomas Using Annexin-Based Optical Fluorescence Imaging Validated by Perfusion MRI.Arterial blood supply of hepatocellular carcinoma is associated with efficacy of sorafenib therapyImaging-based observational databases for clinical problem solving: the role of informatics.In vivo monitoring of sorafenib therapy effects on experimental prostate carcinomas using dynamic contrast-enhanced MRI and macromolecular contrast media.Monitoring the effects of anti-angiogenesis on the radiation sensitivity of pancreatic cancer xenografts using dynamic contrast-enhanced computed tomography.Tracer-kinetic modeling of dynamic contrast-enhanced MRI and CT: a primer.Differences in perfusion CT parameter values with commercial software upgrades: a preliminary report about algorithm consistency and stability.An empirical mathematical model applied to quantitative evaluation of thioacetamide-induced acute liver injury in rats by use of dynamic contrast-enhanced computed tomography.
P2860

Dynamic contrast-enhanced computed tomography imaging biomarkers correlated with immunohistochemistry for monitoring the effects of sorafenib on experimental prostate carcinomas.

Item
http://www.wikidata.org/entity/Q39470823
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Dynamic contrast-enhanced comp ...... erimental prostate carcinomas.
@en
Dynamic contrast-enhanced comp ...... erimental prostate carcinomas.
@nl
type
label
Dynamic contrast-enhanced comp ...... erimental prostate carcinomas.
@en
Dynamic contrast-enhanced comp ...... erimental prostate carcinomas.
@nl
prefLabel
Dynamic contrast-enhanced comp ...... erimental prostate carcinomas.
@en
Dynamic contrast-enhanced comp ...... erimental prostate carcinomas.
@nl
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
Dynamic contrast-enhanced comp ...... perimental prostate carcinomas
@en
P2093
P304
P31
P356
10.1097/RLI.0B013E3182300FE4
P433
P478
P50
P577
P698
P921